10-Q · May 19, 2026
Mangoceuticals' Q4 2026 results show a significant annual decline in revenue and worsening profitability. Revenue decreased to $67,864, down from $109,306 in Q4 2025, while the net loss narrowed slightly to $3,403,141…
Earnings analysis · 10-Q
MGRX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include current-period revenue, margins, EPS, balance-sheet, segment, or cash-flow figures, so quarter-over-quarter and year-over-year earnings trends cannot be assessed from the…
Read full summary
The provided 10-Q excerpt does not include current-period revenue, margins, EPS, balance-sheet, segment, or cash-flow figures, so quarter-over-quarter and year-over-year earnings trends cannot be assessed from the available text. The principal disclosures are materially negative: the company remains out of compliance with Nasdaq’s $1.00 bid-price requirement despite receiving a compliance extension through February 1, 2027, while the proposed transaction entails approximately 96% ownership by former Nuclea shareholders and requires a minimum $15,000,000 PIPE. Management reported effective disclosure controls as of June 30, 2026, but transaction execution, dilution, compounding regulation, and potential delisting remain significant risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Nasdaq compliance period extended
Nasdaq granted an additional 180-calendar-day compliance period through February 1, 2027 to regain the $1.00 minimum bid price requirement, providing additional time to address the listing deficiency.
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026. The company also added procedures to review journal entries before posting to the general ledger.
-
Consulting arrangement disclosed
On July 27, 2026, the company issued Dorado Goose, LLC 250,000 restricted common shares for a six-month consulting agreement; the issuance was exempt under Section 4(a)(2) and/or Rule 506 of Regulation D.
What to watch
-
Nasdaq delisting remains a material risk
The company remains below Nasdaq’s $1.00 minimum bid price requirement and may also fail the $2.5 million stockholders’ equity, $35 million market-value-of-listed-securities, or $500,000 net-income listing alternatives. The current compliance period ends February 1, 2027, and failure could lead to delisting.
-
Transaction execution and dilution risk
The transaction requires, among other conditions, a minimum $15,000,000 PIPE financing. Former Nuclea shareholders are expected to own approximately 96% of the company on a fully diluted, as-exchanged basis, leaving existing shareholders with approximately 4% before additional PIPE dilution.
-
Compounding regulatory exposure increased
The company relies on a related-party pharmacy operating under Section 503A of the FFD&C Act. Increased FDA scrutiny of telehealth and compounding practices could cause the business to be treated as drug manufacturing, potentially requiring FDA approval and current good manufacturing practice compliance and leading to enforcement actions or discontinued offerings.
Management's outlook
No quantitative financial or operating guidance was provided in the filing excerpt; outlook was deferred to the earnings release or call, if any.
Earlier filings 4
10-K · April 1, 2026
Mangoceuticals reported FY2025 revenue of $456,021 (sum of 2025 quarters: $109,306, $168,109, $84,246, $94,360) but remains deeply unprofitable with extreme negative operating margins across 2025 quarters (e.g.,…
10-K · March 20, 2025
Mangoceuticals positions itself as a telehealth-focused men’s wellness and specialty pharmaceutical seller (compounded RDT products and an FDA‑approved oral testosterone product) while pursuing Phase II trials for a…
10-Q · November 14, 2024
Mangoceuticals reported Q3 revenue of $133,368 and gross profit of $82,671 (62.0% gross margin) but continued to generate sizable operating and net losses (loss from operations $1,758,074; net loss $1,999,694). The…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.